{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T02:36:11Z","timestamp":1776479771035,"version":"3.51.2"},"reference-count":71,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T00:00:00Z","timestamp":1720656000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Maria Sklodowska-Curie National Research Institute of Oncology"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Background. The use of locoregional radiotherapy (RT) in patients with advanced ER-positive, HER2-negative breast cancer remains a topic of ongoing debate. In this study, we aimed to evaluate the efficacy of locoregional RT in advanced breast cancer patients treated with cyclin-dependent kinase 4\/6 inhibitors (CDK4\/6i) in a first-line setting. Methods. We conducted a retrospective analysis of patients diagnosed with advanced breast cancer between 2018 and 2023 who received treatment with CDK4\/6i and underwent locoregional radiotherapy. Results. Among the 371 patients treated with CDK4\/6i as part of their first-line therapy, 23 received locoregional RT either concurrently or sequentially with CDK4\/6 inhibitors. Disease progression within the breast occurred in 19 patients (5.1%). Among these cases, five patients had previously undergone breast RT (5\/23, 21.7%), while 14 did not (14\/348, 4.0%, p = 0.004). All cases of local progression after RT followed palliative doses and were accompanied by early systemic progression. The 2-year PFS in the entire cohort of patients treated with locoregional RT was 65.7% (95% CI: 40.5\u201382.3%). Notably, patients who received higher RT doses had longer 2-year PFS (83.3%, 95% CI: 27.3\u201397.5%) than those with palliative RT doses (59.3%, 95% CI: 30.7\u201379.3%); however, the results were not statistically significant (p = 0.58). Furthermore, the 2-year local control in the entire cohort with locoregional RT was 73.0% (95% CI: 46.5\u201387.9%). Importantly, no local progression was observed after RT when using high doses. Conclusions. The addition of locoregional radiotherapy to first-line CDK4\/6 inhibitors warrants further investigation across various clinical scenarios in advanced breast cancer. Palliative radiation regimens delivered early in breast oligoprogression may not always suffice, emphasizing the need for comprehensive studies in this context.<\/jats:p>","DOI":"10.3390\/ph17070927","type":"journal-article","created":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T16:23:41Z","timestamp":1720801421000},"page":"927","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Locoregional Radiotherapy in Patients with Advanced Breast Cancer Treated with Cyclin-Dependent Kinase 4\/6 Inhibitors Based on Real-World Data"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1877-5691","authenticated-orcid":false,"given":"Marcin","family":"Kubeczko","sequence":"first","affiliation":[{"name":"Breast Cancer Center, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, 44-102 Gliwice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9096-2788","authenticated-orcid":false,"given":"Dorota","family":"Gabry\u015b","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, Maria Sk\u0142odowska-Curie National Research Institute of Oncology, Gliwice Branch, 44-102 Gliwice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Polakiewicz-Gilowska","sequence":"additional","affiliation":[{"name":"Breast Cancer Center, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, 44-102 Gliwice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Bobek-Billewicz","sequence":"additional","affiliation":[{"name":"Radiology and Diagnostic Imaging Department, Maria Sk\u0142odowska-Curie National Research Institute of Oncology, 44-102 Gliwice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Micha\u0142","family":"Jarz\u0105b","sequence":"additional","affiliation":[{"name":"Breast Cancer Center, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, 44-102 Gliwice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,7,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S0140-6736(17)33326-3","article-title":"Global surveillance of trends in cancer survival: Analysis of individual records for 37,513,025 patients diagnosed with one of 18 cancers during 2000\u20132014 from 322 population-based registries in 71 countries (CONCORD-3)","volume":"391","author":"Allemani","year":"2018","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1001\/jamaoncol.2019.4782","article-title":"The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor\u2013Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy\u2014MONARCH 2: A Randomized Clinical Trial","volume":"6","author":"Sledge","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.annonc.2021.05.353","article-title":"Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: Updated overall survival","volume":"32","author":"Slamon","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"101282","DOI":"10.1016\/j.eclinm.2022.101282","article-title":"De novo and recurrent metastatic breast cancer\u2014A systematic review of population-level changes in survival since 1995","volume":"44","author":"Lord","year":"2022","journal-title":"EClinicalMedicine"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1056\/NEJMoa2114663","article-title":"Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer","volume":"386","author":"Hortobagyi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_6","unstructured":"Dwyer, M. (2023, March 20). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines \u00ae) Breast Cancer NCCN.org NCCN Guidelines for Patients \u00ae. Available online: www.nccn.org\/patients."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1245\/s10434-018-6494-6","article-title":"Randomized Trial Comparing Resection of Primary Tumor with No Surgery in Stage IV Breast Cancer at Presentation: Protocol MF07-01","volume":"25","author":"Soran","year":"2018","journal-title":"Ann. Surg. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/S1470-2045(15)00135-7","article-title":"Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: An open-label randomised controlled trial","volume":"16","author":"Badwe","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1097\/SLA.0000000000002771","article-title":"Impact of Breast Surgery in Primary Metastasized Breast Cancer: Outcomes of the Prospective Randomized Phase III ABCSG-28 POSYTIVE Trial","volume":"269","author":"Fitzal","year":"2019","journal-title":"Ann. Surg."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1200\/JCO.21.02006","article-title":"Early Local Therapy for the Primary Site in De Novo Stage IV Breast Cancer: Results of a Randomized Clinical Trial (EA2108)","volume":"40","author":"Khan","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1758835920943065","DOI":"10.1177\/1758835920943065","article-title":"Health-related quality of life in premenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer treated with ribociclib plus endocrine therapy: Results from a phase III randomized clinical trial (MONALEESA-7)","volume":"12","author":"Harbeck","year":"2020","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e200643","DOI":"10.1001\/jamanetworkopen.2020.0643","article-title":"Association of Disease Progression with Health-Related Quality of Life Among Adults with Breast, Lung, Pancreatic, and Colorectal Cancer","volume":"3","author":"Marschner","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"5282","DOI":"10.1038\/s41598-021-84872-9","article-title":"Palliative radiation therapy for symptomatic advance breast cancer","volume":"11","author":"Jacobson","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/S1470-2045(21)00539-8","article-title":"European Society for Radiotherapy and Oncology Advisory Committee in Radiation Oncology Practice consensus recommendations on patient selection and dose and fractionation for external beam radiotherapy in early breast cancer","volume":"23","author":"Meattini","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_16","first-page":"173","article-title":"Locoregional therapy in de novo metastatic breast cancer: Systemic review and meta-analysis","volume":"58","author":"Reinhorn","year":"2021","journal-title":"Breast Off. J. Eur. Soc. Mastology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and Letrozole in Advanced Breast Cancer","volume":"375","author":"Finn","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41523-018-0097-z","article-title":"MONARCH 3 final PFS: A randomized study of abemaciclib as initial therapy for advanced breast cancer","volume":"5","author":"Johnston","year":"2019","journal-title":"NPJ Breast Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1093\/annonc\/mdy155","article-title":"Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer","volume":"29","author":"Hortobagyi","year":"2018","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1200\/JCO.2018.78.9909","article-title":"Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3","volume":"36","author":"Slamon","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/S1470-2045(18)30292-4","article-title":"Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): A randomised phase 3 trial","volume":"19","author":"Tripathy","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s13058-023-01701-9","article-title":"Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+\/HER2\u2212 advanced breast cancer receiving first-line ribociclib plus fulvestrant","volume":"25","author":"Neven","year":"2023","journal-title":"Breast Cancer Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e1339","DOI":"10.1002\/onco.13833","article-title":"Prognostic Factors for Overall Survival in Patients with Hormone Receptor-Positive Advanced Breast Cancer: Analyses From PALOMA-3","volume":"26","author":"Rugo","year":"2021","journal-title":"Oncologist"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s13058-018-1050-7","article-title":"Ribociclib for the first-line treatment of advanced hormone receptor-positive breast cancer: A review of subgroup analyses from the MONALEESA-2 trial","volume":"20","author":"Hortobagyi","year":"2018","journal-title":"Breast Cancer Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3433","DOI":"10.1158\/1078-0432.CCR-22-0305","article-title":"Overall Survival with Palbociclib and Fulvestrant in Women with HR+\/HER2- ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study","volume":"28","author":"Cristofanilli","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/S1470-2045(20)30642-2","article-title":"Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): Interim analysis of a multicentre, open-label, randomised, phase 3 study","volume":"22","author":"Mayer","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"17588359231178125","DOI":"10.1177\/17588359231178125","article-title":"Rationale and trial design of NATALEE: A Phase III trial of adjuvantribociclib\u2009+\u2009endocrine therapy versus endocrine therapy alonein patients with HR+\/HER2\u2212 early breast cancer","volume":"15","author":"Slamon","year":"2023","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1200\/JCO.20.02514","article-title":"Abemaciclib Combined with Endocrine Therapy for the Adjuvant Treatment of HR+, HER2\u2212, Node-Positive, High-Risk, Early Breast Cancer (monarchE)","volume":"38","author":"Johnston","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1016\/S1470-2045(23)00534-X","article-title":"International multidisciplinary consensus on the integration of radiotherapy with new systemic treatments for breast cancer: European Society for Radiotherapy and Oncology (ESTRO)-endorsed recommendations","volume":"25","author":"Meattini","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"109839","DOI":"10.1016\/j.radonc.2023.109839","article-title":"Safety and feasibility of CDK4\/6 inhibitors treatment combined with radiotherapy in patients with HR-positive\/HER2-negative breast cancer. A systematic review and meta-analysis","volume":"187","author":"Kubeczko","year":"2023","journal-title":"Radiother. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"102586","DOI":"10.1016\/j.ctrv.2023.102586","article-title":"Safety profile of cyclin-dependent kinase (CDK) 4\/6 inhibitors with concurrent radiation therapy: A systematic review and meta-analysis","volume":"119","author":"Becherini","year":"2023","journal-title":"Cancer Treat. Rev."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1002\/ijc.34562","article-title":"Outcomes and toxicity of concurrent CDK4\/6 inhibitor and locoregional radiotherapy for patients with de novo metastatic breast cancer","volume":"153","author":"Beddok","year":"2023","journal-title":"Int. J. Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1038\/s41598-020-59908-1","article-title":"Locoregional therapy of the primary tumour in de novo stage IV breast cancer in 216 066 patients: A meta-analysis","volume":"10","author":"Gera","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.prro.2023.11.001","article-title":"Partial Breast Irradiation for Patients with Early-Stage Invasive Breast Cancer or Ductal Carcinoma In Situ: An ASTRO Clinical Practice Guideline","volume":"14","author":"Shaitelman","year":"2024","journal-title":"Pract. Radiat. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/j.cell.2009.11.025","article-title":"Tumor Self-Seeding by Circulating Cancer Cells","volume":"139","author":"Kim","year":"2009","journal-title":"Cell"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.surg.2013.02.002","article-title":"Resection of the primary tumor improves survival in metastatic breast cancer by reducing overall tumor burden","volume":"153","author":"Rashid","year":"2013","journal-title":"Surgery"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ejca.2021.11.025","article-title":"Treatment with ribociclib shows favourable immunomodulatory effects in patients with hormone receptor-positive breast cancer-findings from the RIBECCA trial","volume":"162","author":"Peuker","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Kubeczko, M., Gabry\u015b, D., Gawkowska, M., Polakiewicz-Gilowska, A., Cortez, A.J., Krzywon, A., Wo\u017aniak, G., Latusek, T., Le\u015bniak, A., and \u015awiderska, K. (2023). Safety and Feasibility of Radiation Therapy Combined with CDK 4\/6 Inhibitors in the Management of Advanced Breast Cancer. Cancers, 15.","DOI":"10.3390\/cancers15030690"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e65","DOI":"10.1016\/j.clbc.2021.07.013","article-title":"Incidence and Severity of Myelosuppression with Palbociclib After Palliative Bone Radiation in Advanced Breast Cancer: A Single Center Experience and Review of Literature","volume":"22","author":"Norman","year":"2022","journal-title":"Clin. Breast Cancer"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.adro.2019.03.011","article-title":"Safety and Efficacy of Palbociclib and Radiation Therapy in Patients with Metastatic Breast Cancer: Initial Results of a Novel Combination","volume":"4","author":"Chowdhary","year":"2019","journal-title":"Adv. Radiat. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.breast.2019.05.001","article-title":"Concurrent radiotherapy with palbociclib or ribociclib for metastatic breast cancer patients: Preliminary assessment of toxicity","volume":"46","author":"Ippolito","year":"2019","journal-title":"Breast"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s11060-019-03260-6","article-title":"CDK 4\/6 inhibitors and stereotactic radiation in the management of hormone receptor positive breast cancer brain metastases","volume":"144","author":"Figura","year":"2019","journal-title":"J. Neurooncol"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.breast.2018.08.096","article-title":"Ribociclib plus letrozole and concomitant palliative radiotherapy for metastatic breast cancer","volume":"42","author":"Meattini","year":"2018","journal-title":"Breast"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.radonc.2017.09.010","article-title":"Preliminary results of the association of Palbociclib and radiotherapy in metastatic breast cancer patients","volume":"126","author":"Hans","year":"2018","journal-title":"Radiother. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Kubeczko, M., Jarz\u0105b, M., Krzywon, A., Gr\u00e4upner, D., Polakiewicz-Gilowska, A., and Gabry\u015b, D. (2023). Efficacy of CDK 4\/6 Inhibitors and Radiotherapy in Breast Cancer Patients with Brain Metastases. J. Clin. Med., 12.","DOI":"10.3390\/jcm12052044"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.ijrobp.2022.07.005","article-title":"Radiation Therapy with Cyclin-Dependent Kinase 4\/6 Inhibitors: A Multi-institutional Safety and Toxicity Study","volume":"114","author":"Quirk","year":"2022","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.radonc.2022.10.023","article-title":"Safety of CDK4\/6 inhibitors and concomitant radiation therapy in patients affected by metastatic breast cancer","volume":"177","author":"Visani","year":"2022","journal-title":"Radiother. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1007\/s12282-022-01422-5","article-title":"Incidence of and risk factors for non-hematologic toxicity with combined radiotherapy and CDK4\/6 inhibitors in metastatic breast cancer using dose-volume parameters analysis: A multicenter cohort study","volume":"30","author":"Kawamoto","year":"2022","journal-title":"Breast Cancer"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.clbc.2020.05.013","article-title":"Cyclin-Dependent Kinase 4\/6 Inhibitors Combined with Radiotherapy for Patients with Metastatic Breast Cancer","volume":"20","author":"Ratosa","year":"2020","journal-title":"Clin. Breast Cancer"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e99","DOI":"10.1016\/j.clon.2020.10.005","article-title":"Does Concurrent Use of CDK4\/6 Inhibitors during Palliative Radiotherapy Increase Toxicity in Patients with Metastatic Breast Cancer?","volume":"33","author":"Howlett","year":"2021","journal-title":"Clin. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.breast.2021.10.001","article-title":"Safety of cyclin-dependent kinase4\/6 inhibitor combined with palliative radiotherapy in patients with metastatic breast cancer","volume":"60","author":"Kim","year":"2021","journal-title":"Breast"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/s41416-020-0957-9","article-title":"Concurrent use of palbociclib and radiation therapy: Single-centre experience and review of the literature","volume":"123","author":"Beddok","year":"2020","journal-title":"Br. J. Cancer"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"13589","DOI":"10.1038\/s41598-020-70430-2","article-title":"A single-center retrospective safety analysis of cyclin-dependent kinase 4\/6 inhibitors concurrent with radiation therapy in metastatic breast cancer patients","volume":"10","author":"Guerini","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_54","first-page":"100573","article-title":"Real-world time trends in overall survival, treatments and patient characteristics in HR+\/HER2\u2212 metastatic breast cancer: An observational study of the SONABRE Registry","volume":"26","author":"Meegdes","year":"2023","journal-title":"Lancet Reg. Health-Eur."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"5108","DOI":"10.21037\/tcr.2020.02.54","article-title":"Radiation therapy for primary tumor of de novo stage IV breast cancer","volume":"9","author":"Yoshimura","year":"2020","journal-title":"Transl. Cancer Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.1038\/s41598-023-29888-z","article-title":"The optimization of postoperative radiotherapy in de novo stage IV breast cancer: Evidence from real-world data to personalize treatment decisions","volume":"13","author":"Miyashita","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Merloni, F., Palleschi, M., Gianni, C., Casadei, C., Curcio, A., Romeo, A., Rocchi, M., Cima, S., Sirico, M., and Sarti, S. (2023). Locoregional treatment of de novo stage IV breast cancer in the era of modern oncology. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1083297"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1200\/JCO.22.00338","article-title":"Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial","volume":"40","author":"Bidard","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","article-title":"Alpelisib for PIK3CA -Mutated, Hormone Receptor\u2013Positive Advanced Breast Cancer","volume":"380","author":"Ciruelos","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1470-2045(21)00034-6","article-title":"Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4\/6 inhibitor (BYLieve): One cohort of a phase 2, multicentre, open-label, non-comparative study","volume":"22","author":"Rugo","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa1802905","article-title":"Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation","volume":"379","author":"Litton","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"3989","DOI":"10.1158\/0008-5472.CAN-23-0694","article-title":"The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER+ Breast Cancer Growth and Overcomes Endocrine and CDK4\/6 Inhibitor Resistance","volume":"83","author":"Lawson","year":"2023","journal-title":"Cancer Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"TPS1123","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS1123","article-title":"INAVO121: Phase III study of inavolisib (INAVO) + fulvestrant (FUL) vs. alpelisib (ALP) + FUL in patients (pts) with hormone receptor-positive, HER2-negative (HR+, HER2\u2212) PIK3CA-mutated (mut) locally advanced or metastatic breast cancer (LA\/mBC)","volume":"41","author":"Juric","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(23)01245-X","article-title":"Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): A randomised, open-label, multicentre, phase 3 trial","volume":"402","author":"Rugo","year":"2023","journal-title":"Lancet"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1056\/NEJMoa1914609","article-title":"Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer","volume":"382","author":"Murthy","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0140-6736(22)02420-5","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: Updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial","volume":"401","author":"Hurvitz","year":"2023","journal-title":"Lancet (Lond. Engl.)"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa2202809","article-title":"Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer","volume":"387","author":"Cortes","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/17\/7\/927\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:13:07Z","timestamp":1760109187000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/17\/7\/927"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,11]]},"references-count":71,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,7]]}},"alternative-id":["ph17070927"],"URL":"https:\/\/doi.org\/10.3390\/ph17070927","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,11]]}}}